8-K: Mosaic ImmunoEngineering to Acquire Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics

Mosaic ImmunoEngineering has agreed to acquire clinical-stage necroptosis cancer therapy assets and AI technology from Oncotelic Therapeutics in a deal involving stock and potential milestone payments.

Summary

• Mosaic ImmunoEngineering has entered into a binding term sheet to acquire certain assets and technologies from Oncotelic Therapeutics.
• The acquisition includes rights to Oncotelic's clinical-stage necroptosis cancer therapies, particularly those associated with vascular disruptive agents (VDAs).
• Mosaic will also gain non-exclusive access to Oncotelic's AI technologies for identifying immunotherapy combinations.
• The initial consideration is 47,923,322 unregistered shares of Mosaic common stock, valued at $15.0 million, based on a price of $0.313 per share.
• Additional consideration of up to $15.0 million in Mosaic common stock is contingent on achieving mutually agreed-upon milestones within four years.
• These milestones are related to licensing transactions that result in at least $15.0 million in aggregate cash proceeds.
• Mosaic will continue development work with an annual budget of $2.0 to $2.5 million.
• Oncotelic will provide a loan to cover Mosaic's operational costs until June 1, 2024, which will be repaid in cash or shares.
• Mosaic will seek to raise $2.0 million in equity financing to fund its operations.
• If Mosaic cannot secure sufficient funding, the transaction may proceed as a reverse merger of an Oncotelic subsidiary into Mosaic.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook due to the acquisition of promising assets and technologies, but there are risks associated with financing and the potential for a reverse merger. The sentiment is cautiously optimistic.

Positives

• Mosaic gains access to clinical-stage assets, accelerating its pipeline development.
• The acquisition includes valuable regulatory and clinical data packages.
• Access to Oncotelic's AI technology enhances Mosaic's research capabilities.
• The deal structure includes potential for significant upside through milestone payments.
• Oncotelic's financial support provides short-term stability for Mosaic.
• The combined experience of both teams is expected to accelerate the development of the technologies.

Negatives

• The transaction is subject to customary due diligence and shareholder approval.
• Mosaic needs to raise $2.0 million in equity financing to support operations.
• The transaction may convert to a reverse merger if financing is not secured.
• The earn-out consideration is dependent on achieving specific licensing milestones.
• The value of the earn-out consideration is dependent on the share price at the time of issuance.

Risks

• The transaction may not be completed if due diligence is unsatisfactory or if shareholder approval is not obtained.
• Mosaic may not be able to raise the necessary $2.0 million in equity financing.
• The development of the acquired technologies may face delays or setbacks.
• The milestone payments may not be achieved, limiting the potential upside for Oncotelic.
• The reverse merger scenario could result in significant changes to Mosaic's management and structure.
• The value of Mosaic's stock may fluctuate, impacting the value of the consideration.

Future Outlook

Mosaic intends to advance the acquired technologies into clinical trials and build a pipeline of oncology products. The company will work closely with Oncotelic to ensure a smooth transfer of the technologies and secure necessary funding.

Management Comments

• Steven King, President and CEO of Mosaic, stated they are pleased to bring clinical stage assets into the company and look forward to working with Oncotelic to complete the transaction.
• Dr. Vuong Trieu, CEO of Oncotelic, expressed delight in collaborating with Mosaic to advance their AI-driven necroptosis cancer therapies.

Industry Context

This acquisition reflects a trend in the biotechnology industry where companies are seeking to expand their pipelines through strategic acquisitions of promising assets and technologies. The focus on necroptosis and AI-driven drug development aligns with current trends in cancer research and treatment.

Comparison to Industry Standards

• The acquisition of clinical-stage assets is a common strategy for biotech companies looking to accelerate their development timelines, similar to acquisitions made by companies like Gilead and AbbVie.
• The use of AI in drug discovery and development is becoming increasingly prevalent, with companies like Recursion Pharmaceuticals and Exscientia leading the way.
• The deal structure, involving upfront stock and milestone payments, is typical in biotech acquisitions, similar to deals seen in the oncology space.
• The focus on immunotherapies and vascular disrupting agents aligns with current trends in cancer treatment, with companies like Bristol Myers Squibb and Merck leading in these areas.

Stakeholder Impact

• Shareholders of Mosaic may see potential value creation through the acquisition of new assets.
• Employees of both companies may experience changes due to the integration of operations.
• Customers and patients may benefit from the development of new cancer therapies.
• Suppliers and creditors may be impacted by the financial transactions and potential reverse merger.

Next Steps

• Mosaic and Oncotelic will negotiate definitive agreements for the transaction.
• Both parties will conduct due diligence.
• Mosaic will seek shareholder approval for the transaction.
• Mosaic will attempt to raise $2.0 million in equity financing.
• The companies will work together to transfer the technologies from Oncotelic to Mosaic.
• Mosaic will advance the development of the acquired technologies.

Key Dates

Keywords

Acquisition, Necroptosis, Cancer Therapy, Immunotherapy, Vascular Disruptive Agents, AI, Biotechnology, Oncology, Clinical Stage, Milestone Payments